FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
Daniel L. Suzman(United States Food and Drug Administration), Julia A. Beaver(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University), Shenghui Tang(United States Food and Drug Administration), Jason Schroeder(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Sundeep Agrawal(Center for Drug Evaluation and Research), Kirsten B. Goldberg(United States Food and Drug Administration), Laura L. Fernandes(United States Food and Drug Administration), Stella Karuri(United States Food and Drug Administration), Amy E. McKee(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Yang‐Min Ning(United States Food and Drug Administration), V. Ellen Maher(United States Food and Drug Administration)
Cited by 200
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k